This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (116)  • Contact me when this article is cited  Related Content  • Related letter  • Related articles  • Similar articles in JAMA  Social Bookmarking   What's this?

XIX. Applying Clinical Trial Results

A. How to Use an Article Measuring the Effect of an Intervention on Surrogate End Points

Heiner C. Bucher, MD, MPH; Gordon H. Guyatt, MD, MSc; Deborah J. Cook, MD, MSc; Anne Holbrook, MD, MSc; Finlay A. McAlister, MD; for the Evidence-Based Medicine Working Group

JAMA. 1999;282:771-778.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

CLINICAL SCENARIO

You are a physician seeing a 62-year-old woman with postmenopausal osteoporosis. Her bone mineral density, as measured by dual-energy x-ray absorptiometry, is 2.5 SDs below the mean value in premenopausal women. Although she does not have back pain, a spinal radiograph shows an old vertebral fracture. The patient has not yet experienced problems as a result of her vertebral fracture, but she is disturbed by the prospect that she may end up like her mother whose osteoporotic fractures have resulted in severe, long-term back pain.

The patient has reflux esophagitis and a past endoscopy revealed nonspecific gastritis. A specialist had prescribed alendronate, which the patient had to stop taking after several weeks because of dyspepsia. She searched the Web and discovered . . . [Full Text of this Article]

THE SEARCH

INTRODUCTION

THE GUIDES

Are the Results Valid? Is There a Strong, Independent, Consistent Association Between the Surrogate End Point and the Clinical End Point?

Is There Evidence From Randomized Trials in Other Drug Classes That Improvement in the Surrogate End Point Has Consistently Led to Improvement in the Target Outcome?

Is There Evidence From Randomized Trials in the Same Drug Class That Improvement in the Surrogate End Point Has Consistently Led to Improvement in the Target Outcome?

What Were the Results? How Large, Precise, and Lasting Was the Treatment Effect?

Will the Results Help in Caring for My Patients?

Are the Likely Treatment Benefits Worth the Potential Harms and Costs?

RESOLUTION OF THE SCENARIO

Author Affiliations: Medizinische Universitäts-Poliklinik, Kantonsspital Basel, Basel, Switzerland (Dr Bucher); Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario (Drs Guyatt, Cook, and Holbrook); and Division of General Internal Medicine, University of Alberta Hospital, Edmonton (Dr McAlister).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Acetylcysteine and Renal Function Following Coronary Angiographic Procedures—Reply
Jay Kay
JAMA. 2003;289(21):2796.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Surrogate End Points, Health Outcomes, and the Drug-Approval Process for the Treatment of Risk Factors for Cardiovascular Disease
Bruce M. Psaty, Noel S. Weiss, Curt D. Furberg, Thomas D. Koepsell, David S. Siscovick, Frits R. Rosendaal, Nicholas L. Smith, Susan R. Heckbert, Robert C. Kaplan, Danyu Lin, Thomas R. Fleming, and Edward H. Wagner
JAMA. 1999;282(8):786-790.
EXTRACT | FULL TEXT  

Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?
Robert Temple
JAMA. 1999;282(8):790-795.
EXTRACT | FULL TEXT  

August 25, 1999
JAMA. 1999;282(8):803-804.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Systematic Review of Screening for Bilirubin Encephalopathy in Neonates
Trikalinos et al.
Pediatrics 2009;124:1162-1171.
ABSTRACT | FULL TEXT  

Biomarkers in Chronic Obstructive Pulmonary Disease
Sin and Vestbo
Proc Am Thorac Soc 2009;6:543-545.
ABSTRACT | FULL TEXT  

The Development of Urinary Biomarkers for Kidney Disease Is the Search for Our Renal Troponin
Szczech
J. Am. Soc. Nephrol. 2009;20:1656-1657.
FULL TEXT  

End points for clinical trials in acute heart failure syndromes.
Allen et al.
J Am Coll Cardiol 2009;53:2248-2258.
ABSTRACT | FULL TEXT  

Clara Cell Protein CC16: A New Lung Epithelial Biomarker for Acute Lung Injury
McAuley and Matthay
Chest 2009;135:1408-1410.
FULL TEXT  

Author Response
Hammer and Lindmark
ptjournal 2009;89:541-542.
FULL TEXT  

RAGE: a biomarker for acute lung injury
Griffiths and McAuley
Thorax 2008;63:1034-1036.
FULL TEXT  

Patient-Important Outcomes in Registered Diabetes Trials
Gandhi et al.
JAMA 2008;299:2543-2549.
ABSTRACT | FULL TEXT  

Biomarkers in COPD: Are We There Yet?
Sin and Man
Chest 2008;133:1296-1298.
FULL TEXT  

Review: Surfactant protein D: A lung specific biomarker in COPD?
Sin et al.
Ther Adv Respir Dis 2008;2:65-74.
ABSTRACT  

Sevelamer: a promising but unproven drug
Palmer et al.
Nephrol Dial Transplant 2007;22:2742-2745.
FULL TEXT  

Accreditation Council for Graduate Medical Education Competencies: Practice-Based Learning and Systems-Based Practice
Moskowitz and Nash
American Journal of Medical Quality 2007;22:351-382.
 

Documenting research in scientific articles: guidelines for authors: reporting research designs and activities.
Lang
Chest 2006;130:1263-1268.
FULL TEXT  

Weighing the evidence to formulate dietary guidelines.
Woolf
J. Am. Coll. Nutr. 2006;25:277S-284S.
ABSTRACT | FULL TEXT  

Evidence-Based Clinical Practice: Dispelling the Myths
Hise et al.
Nutr Clin Pract 2005;20:294-302.
ABSTRACT | FULL TEXT  

Searching for Evidence-Based Medicine in the Literature Part 3: Assessment
Bartkowiak
Clin Med Res 2005;3:113-115.
FULL TEXT  

From knowledge to practice in chronic cardiovascular disease: a long and winding road
Majumdar et al.
J Am Coll Cardiol 2004;43:1738-1742.
ABSTRACT | FULL TEXT  

Assessment of Anxiety in Intensive Care Patients By Using the Faces Anxiety Scale
McKinley et al.
Am J Crit Care 2004;13:146-152.
ABSTRACT | FULL TEXT  

How to spot bias and other potential problems in randomised controlled trials
Lewis and Warlow
J. Neurol. Neurosurg. Psychiatry 2004;75:181-187.
FULL TEXT  

Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials
Yazdanpanah et al.
BMJ 2004;328:249.
ABSTRACT | FULL TEXT  

Effects of Computerized Physician Order Entry and Clinical Decision Support Systems on Medication Safety: A Systematic Review
Kaushal et al.
Arch Intern Med 2003;163:1409-1416.
ABSTRACT | FULL TEXT  

Acetylcysteine and Renal Function Following Coronary Angiographic Procedures
Bagshaw and Culleton
JAMA 2003;289:2795-2795.
FULL TEXT  

Acetylcysteine and Renal Function Following Coronary Angiographic Procedures--Reply
Kay
JAMA 2003;289:2796-2796.
FULL TEXT  

Applying Evidence to Patient Care: From Black and White to Shades of Grey
McAlister
ANN INTERN MED 2003;138:938-939.
FULL TEXT  

Safe but Sound: Patient Safety Meets Evidence-Based Medicine
Shojania et al.
JAMA 2002;288:508-513.
FULL TEXT  

Medical Education, Evidence-Based Medicine, and the Disqualification of Physician-Scientists
Sobel and Levine
Exp. Biol. Med. 2001;226:713-716.
FULL TEXT  

How Many Steps of Progression of Diabetic Retinopathy Are Meaningful?: The Wisconsin Epidemiologic Study of Diabetic Retinopathy
Klein et al.
Arch Ophthalmol 2001;119:547-553.
ABSTRACT | FULL TEXT  

Erythropoietin: A Paradigm for the Development of Practice Guidelines
Rizzo et al.
ASH Education Book 2001;2001:10-30.
ABSTRACT | FULL TEXT  

Users' Guides to the Medical Literature: XIX. Applying Clinical Trial Results; B. Guidelines for Determining Whether a Drug Is Exerting (More Than) a Class Effect
McAlister et al.
JAMA 1999;282:1371-1377.
FULL TEXT  

Estimating the population impact of an intervention: a decision-analytic approach
Hersh et al.
Stat Methods Med Res 1999;8:311-330.
ABSTRACT